A Review of Guselkumab - an IL-23 Inhibitor for Psoriasis

Skin Therapy Letter-Family Practice Edition

Zeena Nawas¹  Yun Tong¹  Michael Hatch¹  Elmira Ramos¹  Melinda Liu¹ 

[1] 1Center For Clinical Studies, Houston, TX, USA

关键词: biologics;    cytokine;    IL-23;    interleukin-23 inhibitor;    monoclonal antibody;    psoriasis;    Th17;   

学科分类：医学（综合）

来源: Skin Therapy Letter-Family Practice Edition

【 摘 要 】

Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Data from Phase I-III trials in this patient population reveal that guselkumab has proven to be superior to placebo or adalimumab based on achieving a Psoriasis Area and Severity Index (PASI) 90% reduction, or a static Physician Global Assessment (sPGA) score of 0 or 1 from baseline. This article reviews the current status of guselkumab as a therapy for moderate-to-severe plaque psoriasis.

【 授权许可】

CC BY